Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sintilimab and Trastuzumab with SOX in HER2+ Gastric Cancer
NCT05218148Phase 2Not yet recruiting
- Start
- Apr 2022
- Primary completion
- Oct 2024
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of sintilimab, trastuzumab in gastric adenocarcinoma, gastroesophageal junction adenocarcinoma. Planned start Apr 2022; status: not yet recruiting.
02
Drugs
sintilimabtrastuzumab
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NCT05218148.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05218148.